Alnylam data files CTA with the U.

Alnylam data files CTA with the U .K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics business, announced today that it has filed a Clinical Trial Program with the U.K. Medicines and Healthcare products Regulatory Company to initiate a Stage I medical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin for the treating TTR-mediated amyloidosis . ALN-TTR02 is a shipped RNAi therapeutic systemically, targeting the TTR gene, that comprises an siRNA formulated in a second-generation lipid nanoparticle .

The report was published online March 17 as a extensive research letter in JAMA Internal Medication. Suggestions from the American Academy of Family Physicians, American Academy of Neurology and the American College of Emergency Physicians recommend against routine brain scans for headache . The scholarly study cannot verify whether scans were ordered according to guidelines or not, but showed that they happened in the context of a headache-related go to to a doctor. ‘Though this study shows levels of imaging that are unquestionably extreme and costs that probably go beyond the benefits, it generally does not measure or discuss the benefits of brain imaging in individuals with headache,’ said Dr. Richard Lipton, vice chairman of director and neurology of the Montefiore Headache Center at the Albert Einstein College of Medicine, in New York City.